



Application Number: 2I01BX002761-05

Principal Investigator(s):

Amar B Singh, PHD

Project Title: Claudin-3, Gut Dysbiosis and Inflammatory Bowel Disease

Hamel, Frederick

OMAHA VA MEDICAL CENTER

4101 Woolworth Avenue (151)

Omaha, NE 681051850

Budget Period: 04/01/2020 – 03/31/2021

Project Period: 04/01/2016 – 03/31/2024

We are pleased to inform you that funding in the amount of \$309,729 (see "Proposed Award Data" in Section I) is being awarded to support the above named project. Funds will be provided by fiscal year according to the award calculation and the budget start date. The funding amounts cited in this Notice of Award may not match the allocations provided to your medical center because funds are provided to VA sites by fiscal year. The VA fiscal year starts on October 1st and ends on September 30th each year. Minor changes to the budget will not be reflected here but can be found in the "Pink Sheet" generated from the VA RAFT program. Contact the VA Research Office at your medical center to obtain a copy of your "Pink Sheet" which will provide you with fiscal year funding amounts and will incorporate changes to the budget.

Please refer to Section III for Terms and Conditions of the award.

If you have questions about this award, please contact the individual(s) referenced in Section II below.

SECTION I – PROPOSED AWARD DATA – 2I01BX002761-05

SUMMARY OF PROPOSED TOTALS FOR ALL YEARS	
YR	AWARD
5	\$309,729
6	\$261,624
7	\$263,556
8	\$265,527

Recommended future year total cost support is subject to the availability of funds and satisfactory progress of the project.

SECTION II – CONTACT INFORMATION – 2I01BX002761-05

The Program Officer (PO) named below is responsible for the scientific, programmatic and technical aspects of this project.

PO: Kenute Myrie

Email: kenute.myrie@va.gov Phone: 202-443-5674

SECTION III – TERMS AND CONDITIONS – 2I01BX002761-05

This award is based on the application submitted to and approved by VA-ORD and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. Award recipients must adhere to VA research policies including VA requirements for progress reports (RPPRs); final reports; research publications; public access to data; intellectual property; and clinical trial registration and reporting required by clinicaltrials.gov.
- b. All awards are dependent upon the availability of funds.
- c. Awards should be carried out according to the plan presented in the approved application. Any significant changes in project duration, budget, aims, methods, site(s) or PI must be approved by Biomedical Laboratory Research & Development. Project modifications may be requested using the ORD Project Modification Form located on the Office of Research & Development website at <http://www.research.va.gov/resources/policies/default.cfm>.



NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

Grant Number: 1R01DK124095-01A1
FAIN: R01DK124095

Principal Investigator(s):

David Oupicky (contact), PHD
Amar B Singh, PHD

Project Title: Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease

Vetter, Deborah K
Director, Sponsored Programs
987835 Nebraska Medical Center
Omaha, NE 681987835

Award e-mailed to: spadmin@unmc.edu

Period Of Performance:

Budget Period: 04/01/2020 – 02/28/2021

Project Period: 04/01/2020 – 02/29/2024

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$517,434 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF NEBRASKA MEDICAL CENTER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Diabetes And Digestive And Kidney Diseases of the National Institutes of Health under Award Number R01DK124095. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Jeni Smits
Grants Management Officer
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

Additional information follows



Application Number: 2I01BX002086-06A1

Principal Investigator(s):

PUNITA DHAWAN, PHD

Project Title: Role of claudin-1 in Colon Cancer

Hamel, Frederick

Acting ACOS

4101 Woolworth Avenue (151)

Omaha, NE 681051850

Budget Period: 10/01/2018 – 09/30/2019

Project Period: 07/01/2013 – 09/30/2022

We are pleased to inform you that funding in the amount of \$286,940 (see "Proposed Award Data" in Section I) is being awarded to support the above named project. Funds will be provided by fiscal year according to the award calculation and the budget start date. The funding amounts cited in this Notice of Award may not match the allocations provided to your medical center because funds are provided to VA sites by fiscal year. The VA fiscal year starts on October 1st and ends on September 30th each year. Minor changes to the budget will not be reflected here but can be found in the "Pink Sheet" generated from the VA RAFT program. Contact the VA Research Office at your medical center to obtain a copy of your "Pink Sheet" which will provide you with fiscal year funding amounts and will incorporate changes to the budget.

Please refer to Section III for Terms and Conditions of the award.

If you have questions about this award, please contact the individual(s) referenced in Section II below.

SECTION I – PROPOSED AWARD DATA – 2I01BX002086-06A1

SUMMARY OF PROPOSED TOTALS FOR ALL YEARS	
YR	AWARD
6	\$286,940
7	\$238,679
8	\$240,452
9	\$242,261

Recommended future year total cost support is subject to the availability of funds and satisfactory progress of the project.

SECTION II – CONTACT INFORMATION – 2I01BX002086-06A1

The Program Officer (PO) named below is responsible for the scientific, programmatic and technical aspects of this project.

PO: Kenute Myrie

Email: kenute.myrie@va.gov Phone: 202-443-5674

SECTION III – TERMS AND CONDITIONS – 2I01BX002086-06A1

This award is based on the application submitted to and approved by VA-ORD and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. Award recipients must adhere to VA research policies including VA requirements for progress reports (RPPRs); final reports; research publications; public access to data; intellectual property; and clinical trial registration and reporting required by clinicaltrials.gov.
- b. All awards are dependent upon the availability of funds.
- c. Awards should be carried out according to the plan presented in the approved application. Any significant changes in project duration, budget, aims, methods, site(s) or PI must be approved by Biomedical Laboratory Research & Development. Project modifications may be requested using the ORD Project Modification Form located on the Office of Research & Development website at <http://www.research.va.gov/resources/policies/default.cfm>.



NATIONAL CANCER INSTITUTE

Grant Number: 1R21CA216746-01A1
FAIN: R21CA216746

Principal Investigator(s):
PUNITA DHAWAN, PHD

Project Title: Mastl, a novel therapeutic target in Colon Cancer

Deborah K Vetter
Director, Sponsored Programs
987835 Nebraska Medical Center
Omaha, NE 681987835

Award e-mailed to: spadmin@unmc.edu

Period Of Performance:

Budget Period: 03/01/2018 – 02/28/2019

Project Period: 03/01/2018 – 02/28/2020

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$165,391 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF NEBRASKA MEDICAL CENTER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R21CA216746. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Tawana McKeither
Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows